| Project/Area Number |
13470247
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
General surgery
|
|---|
| Research Institution | National Cardiovascular Center Research Institute |
|---|
Principal Investigator |
TAKANO Hisateru (2003) National Cardiovascular Center Research Institute, Deputy, 副所長 (60028595)
西中 知博 (2001-2002) 国立循環器病センター研究所, 人工臓器部, 室長 (00256570)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
TSUKIYA Tomonori National Cardiovascular Center Research Institute, Department of Artificial Organs, Staff researcher, 人工臓器部, 室員 (00311449)
TATSUMI Eisuke National Cardiovascular Center Research Institute, Department of Artificial Organs, Laboratory chief, 人工臓器部, 室長 (00216996)
TAENAKA Yoshiyuki National Cardiovascular Center Research Institute, Department of Artificial Organs, Director, 人工臓器部, 部長 (00142183)
本間 章彦 国立循環器病センター研究所, 人工臓器部, 室員 (20287428)
TAKEWA Yoshiaki National Cardiovascular Center Research Institute, Department of Artificial Organs, Laboratory chief, 人工臓器部, 室長 (20332405)
NISHINAKA Tomohiro National Cardiovascular Center Research Institute, Department of Artificial Organs, Laboratory Chief (00256570)
高野 久輝 国立循環器病センター研究所, 副所長 (60028595)
|
|---|
| Project Period (FY) |
2001 – 2003
|
| Project Status |
Completed (Fiscal Year 2003)
|
| Budget Amount *help |
¥14,000,000 (Direct Cost: ¥14,000,000)
Fiscal Year 2003: ¥3,600,000 (Direct Cost: ¥3,600,000)
Fiscal Year 2002: ¥5,000,000 (Direct Cost: ¥5,000,000)
Fiscal Year 2001: ¥5,400,000 (Direct Cost: ¥5,400,000)
|
|---|
| Keywords | Artificial lung / centrifugal pump / Cardiopulmonary support / anticoagulant therapy / Heparin bonding techenique / ヘパリン / 血液適合性 / 人工心臓 |
|---|
| Research Abstract |
We have develop a new ECMO system which has an excellent antithrombogenicity and durability, aiming at facilitating prolonged ECMO support using newly developed heparin bonding technique (T-NCVC), a newly-developed membrane oxygenator (Platinum Cube NCVC), and a long-term durable centrifugal blood pump. Our results indicated that our newly developed ECMO system possesses a potential to perform prolonged circulatory support with minimum anticoagulants. In the evaluation using animals, all the ECMO systems could be maintained in the stable condition at least up to 65 days without systemic anticoagulants. All the animals except for one were able to be preserved until scheduled termination of experiments. No serum leakage from the oxygenators was observed, and the gas exchange performance was constantly retained. The pump performance was also sustained to deep purposed blood flow, and no significant hemolysis was observed. The changes of blood components and coagulation relating factors were ranged within quite small extent, which indicates that this ECMO system provides high blood compatibility. This ECMO system is an innovative system which has a potential to realize long-term perfusion without anticoagulants and device exchanges. It will realize the improvement of clinical results in the treatment of severe respiratory and/or circulatory distress patients, and furthermore, this system should change the concept of ECMO due to its long-term durability and high antithrombogenicity, especially in the application for such patients with difficulty in the anticoagulant therapy.
|
